Physician profile
Alexander Saker
NPI 1073602751
$3,389.51
in general payments reported to CMS, 2019-2025
39 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.55 · 2021: $196 · 2022: $286 · 2023: $1,717 · 2024: $1,068 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883 · Education: $13.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.10 |
| Education | $13.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $544.63 | 2023-2024 | Myrisk |
| Exelixis INC. | $195.76 | 2021-2025 | Cabometyx |
| Janssen Biotech, INC. | $179.48 | 2023-2024 | Darzalex, Erleada, Talvey |
| Merck Sharp & Dohme LLC | $178.37 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $156.00 | 2019-2024 | |
| Daiichi Sankyo INC. | $155.88 | 2022-2024 | Enhertu |
| Seagen INC. | $155.84 | 2022-2023 | Adcetris, Padcev, Tukysa |
| Glaxosmithkline, LLC. | $140.02 | 2022-2024 | Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $125.58 | 2022-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $124.65 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $121.13 | 2023-2024 | Enhertu, Lynparza, Calquence |
| Celgene Corporation | $107.83 | 2023-2024 | Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $106.27 | 2023-2024 | Opdivo |
| Astellas Pharma US INC | $103.50 | 2023-2025 | Vyloy, Xtandi |
| Eisai INC. | $94.15 | 2022-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Saker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.